IMCD Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
IMCD wird ein jährliches Gewinn- und Umsatzwachstum von 10.4% bzw. 4.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 10% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.2% betragen.
Wichtige Informationen
10.4%
Wachstumsrate der Gewinne
9.97%
EPS-Wachstumsrate
| Trade Distributors Gewinnwachstum | 13.4% |
| Wachstumsrate der Einnahmen | 4.6% |
| Zukünftige Eigenkapitalrendite | 14.21% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 22 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • May 14
IMCD: Margin Execution And Earnings Quality Should Support Future Re Rating
Narrative update on IMCD The updated analyst price target for IMCD moves to €148.67 from €144.05. This change reflects analysts' revised views on growth, profitability and P/E assumptions after recent target changes from major banks across the sector.Narrativ-Update • Apr 29
IMCD: Margin Execution And Revenue Mix Should Support Future Re Rating
Analyst price targets for IMCD have edged lower, with recent cuts of €5 to €7 from several banks and a reset range between about €103 and €122. Analysts are factoring in a slightly higher discount rate, a lower assumed future P/E multiple and updated expectations for revenue growth and margins.
Narrativ-Update • Apr 15
IMCD: Dividend Cut And Lowered Expectations Will Pressure Future Returns
IMCD's updated analyst price target has edged lower by a few euros, with recent revisions between about €103 and €122. These reflect analysts' mixed adjustments to growth, margin and P/E assumptions.
Narrativ-Update • Mar 31
IMCD: Lower Dividend And Reset Expectations Will Set Up Future Upside
The Analyst Price Target for IMCD has shifted lower to €107.68 from €126.46, reflecting analysts' updated views on slightly softer revenue growth, thinner profit margins and a lower future P/E multiple, supported by a series of recent price target cuts and one upward revision across major banks. Analyst Commentary Recent research shows a mix of optimism and caution around IMCD, with several banks trimming price targets and one raising them, which helps explain why the average target has reset closer to current expectations.Narrativ-Update • Mar 17
IMCD: Sector Caution And Dividend Reset Will Shape Future Expectations
Analysts have trimmed the IMCD price target, with recent revisions clustering around €100 to €122. This reflects updated views on sector conditions and modest adjustments to revenue growth, discount rate and profit margin assumptions.Narrativ-Update • Mar 03
IMCD: Sector Caution And New Partnership Will Shape Future Expectations
The analyst fair value estimate for IMCD has been adjusted from €82.00 to €75.00. Analysts cite recent price target changes across major banks, along with more cautious assumptions on discount rates, revenue growth, and margins, as the key drivers of the updated view.Narrativ-Update • Feb 17
IMCD: Distribution Expansion And CFO Transition Will Support Future Re Rating
Analysts have trimmed their price targets for IMCD by about €14, citing slightly higher discount rate assumptions, revised profit margin expectations, and recent cautious sector views. These developments are reflected in lower price targets and a downgrade to Equal Weight.Narrativ-Update • Feb 03
IMCD: Cautious Sector Outlook And New Partnership Will Shape Expectations
Analysts have reduced their fair value estimate for IMCD from €107.00 to €82.00. This reflects a lower future P/E assumption and a slightly reduced profit margin outlook, in line with recent Street research that has turned more cautious on chemical distribution and related services.Narrativ-Update • Jan 20
IMCD: Distribution Deal And CFO Transition Will Support Sector Re Rating
Analysts have lowered their price target on IMCD to about €170.50 from roughly €176.73, citing a reset in sector expectations following cautious views on chemical distribution and a shift in preferred names within European business services. Analyst Commentary Recent research has shifted IMCD to a more neutral stance within European business services, with the rating moved to Equal Weight and the price target set at €100 from €139.Analyseartikel • Jan 20
Is There An Opportunity With IMCD N.V.'s (AMS:IMCD) 50% Undervaluation?
Key Insights IMCD's estimated fair value is €148 based on 2 Stage Free Cash Flow to Equity Current share price of...Narrativ-Update • Jan 06
IMCD: Share Pullback Will Set Up Upside Following New Outperform Coverage
Analysts have trimmed their fair value estimate for IMCD from €127.18 to €126.46, reflecting slightly softer assumptions for revenue growth and profit margin, even as some recent research, including new Outperform coverage, points to potential upside after the recent share pullback. Analyst Commentary Bullish Takeaways Bullish analysts view the recent share pullback as creating a more appealing entry point relative to their updated fair value and the new $72.50 price target.Narrativ-Update • Dec 17
IMCD Will Likely Gain From New Distribution Deal And Leadership Transition
Analysts have trimmed their fair value estimate for IMCD to approximately €177 from about €182, reflecting slightly higher discount rate assumptions, more moderate revenue growth expectations, and a marginally lower future P/E, partially offset by a firmer margin outlook and recent supportive rating actions despite reduced price targets. Analyst Commentary Bullish analysts continue to frame IMCD as a quality compounder within the specialty chemicals distribution space, highlighting the recent share pullback as an opportunity rather than a sign of structural deterioration.Narrativ-Update • Dec 03
IMCD: Share Pullback Will Offer Opportunity As New Outperform Ratings Emerge
The analyst price target for IMCD has been trimmed modestly from EUR 131.25 to about EUR 127.18, as analysts factor in slightly slower growth and margin assumptions, even as they highlight recent upgrades and new Outperform initiations as support for a still constructive outlook. Analyst Commentary Recent research updates point to a broadly constructive stance on IMCD, with most commentary emphasizing resilient fundamentals and an attractive entry point following the share price pullback, even as some valuation and macro risks are flagged.Analyseartikel • Nov 27
Some Shareholders Feeling Restless Over IMCD N.V.'s (AMS:IMCD) P/E Ratio
It's not a stretch to say that IMCD N.V.'s ( AMS:IMCD ) price-to-earnings (or "P/E") ratio of 17.6x right now seems...Narrativ-Update • Nov 19
IMCD: Share Pullback Will Offer Opportunity As Revenue Momentum Builds
IMCD's analyst price target has been revised down from €138.04 to €131.25. Analysts cite moderate adjustments in fair value and market outlook, despite recent supportive coverage and an improved revenue growth forecast.Analyseartikel • Nov 12
Does IMCD (AMS:IMCD) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narrativ-Update • Nov 04
IMCD: Share Price Pullback Will Offer Attractive Entry As Ratings Improve
The analyst fair value estimate for IMCD has been reduced from EUR 142.43 to EUR 138.04. Analysts cite more cautious assumptions on long-term revenue growth and profit margin forecasts following recent price target adjustments in Street research.Analyseartikel • Oct 28
At €93.80, Is IMCD N.V. (AMS:IMCD) Worth Looking At Closely?
IMCD N.V. ( AMS:IMCD ), might not be a large cap stock, but it saw significant share price movement during recent...Narrativ-Update • Oct 21
Analyst Commentary Highlights Mixed Views on IMCD Amid Minor Valuation Adjustments
Analysts have slightly lowered their fair value estimate for IMCD by less than 1 percent to approximately €142.43. This reflects minor adjustments in growth expectations and recent Street research supporting a cautiously positive outlook, despite recent target downgrades.Analyseartikel • Oct 12
Returns On Capital At IMCD (AMS:IMCD) Have Hit The Brakes
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...Narrativ-Update • Oct 03
Digitalization And M&A Will Expand Pharma And Consumer Markets
IMCD's analyst price target has decreased moderately, from €145.43 to €143.00, as analysts factor in slightly lower expected growth and a reduced profit margin outlook in recent industry assessments. Analyst Commentary Analyst opinions on IMCD remain divided as recent price target changes and rating updates reflect a mix of optimism regarding potential growth and caution due to evolving sector dynamics.Narrativ-Update • Sep 04
Digitalization And M&A Will Expand Pharma And Consumer Markets
Analysts cite attractive valuation, improved capital allocation, and stabilizing end markets as supportive, but near-term earnings uncertainty and ongoing macroeconomic headwinds have kept IMCD’s consensus price target unchanged at €145.43. Analyst Commentary Valuation now seen as attractive, with shares offering growth at a reasonable price.Analyseartikel • Sep 01
An Intrinsic Calculation For IMCD N.V. (AMS:IMCD) Suggests It's 44% Undervalued
Key Insights The projected fair value for IMCD is €170 based on 2 Stage Free Cash Flow to Equity IMCD is estimated to...Analyseartikel • Aug 04
We Think IMCD (AMS:IMCD) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Jul 21
There's Reason For Concern Over IMCD N.V.'s (AMS:IMCD) Price
IMCD N.V.'s ( AMS:IMCD ) price-to-earnings (or "P/E") ratio of 23.9x might make it look like a sell right now compared...Analyseartikel • Jul 04
Return Trends At IMCD (AMS:IMCD) Aren't Appealing
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Neues Narrativ • Nov 25
The Company'S Digital Upgrades And M&A Strategy Ignite Growth Potential Amid Challenges
Continued organic growth through commercial excellence and digital upgrades could boost future revenue and earnings.Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 5,589 | 300 | 411 | 431 | 9 |
| 12/31/2027 | 5,296 | 276 | 395 | 415 | 12 |
| 12/31/2026 | 5,103 | 248 | 363 | 414 | 11 |
| 12/31/2025 | 4,805 | 218 | 302 | 322 | N/A |
| 9/30/2025 | 4,822 | 242 | 258 | 281 | N/A |
| 6/30/2025 | 4,839 | 267 | 214 | 240 | N/A |
| 3/31/2025 | 4,793 | 272 | 233 | 260 | N/A |
| 12/31/2024 | 4,747 | 278 | 253 | 279 | N/A |
| 9/30/2024 | 4,653 | 280 | 307 | 337 | N/A |
| 6/30/2024 | 4,559 | 281 | 361 | 395 | N/A |
| 3/31/2024 | 4,511 | 287 | 372 | 407 | N/A |
| 12/31/2023 | 4,463 | 292 | 383 | 420 | N/A |
| 9/30/2023 | 4,527 | 290 | 386 | 418 | N/A |
| 6/30/2023 | 4,590 | 289 | 390 | 416 | N/A |
| 3/31/2023 | 4,606 | 301 | 334 | 358 | N/A |
| 12/31/2022 | 4,622 | 313 | 278 | 299 | N/A |
| 9/30/2022 | 4,357 | 296 | 213 | 232 | N/A |
| 6/30/2022 | 4,091 | 279 | 149 | 165 | N/A |
| 3/31/2022 | 3,772 | 243 | 163 | 181 | N/A |
| 12/31/2021 | 3,453 | 207 | 178 | 196 | N/A |
| 9/30/2021 | 3,257 | 184 | 211 | 229 | N/A |
| 6/30/2021 | 3,060 | 162 | 244 | 262 | N/A |
| 3/31/2021 | 2,924 | 141 | 229 | 247 | N/A |
| 12/31/2020 | 2,787 | 120 | 214 | 232 | N/A |
| 9/30/2020 | 2,752 | 114 | 183 | 203 | N/A |
| 6/30/2020 | 2,717 | 108 | 152 | 173 | N/A |
| 3/31/2020 | 2,711 | 108 | 154 | 174 | N/A |
| 12/31/2019 | 2,705 | 108 | 156 | 174 | N/A |
| 9/30/2019 | 2,670 | 109 | N/A | 157 | N/A |
| 6/30/2019 | 2,636 | 111 | N/A | 139 | N/A |
| 3/31/2019 | 2,512 | 105 | N/A | 127 | N/A |
| 12/31/2018 | 2,389 | 100 | N/A | 114 | N/A |
| 9/30/2018 | 2,260 | 94 | N/A | 102 | N/A |
| 6/30/2018 | 2,131 | 88 | N/A | 90 | N/A |
| 3/31/2018 | 2,022 | 83 | N/A | 102 | N/A |
| 12/31/2017 | 1,912 | 77 | N/A | 114 | N/A |
| 9/30/2017 | 1,840 | 77 | N/A | 112 | N/A |
| 6/30/2017 | 1,768 | 76 | N/A | 110 | N/A |
| 3/31/2017 | 1,743 | 75 | N/A | 105 | N/A |
| 12/31/2016 | 1,718 | 73 | N/A | 100 | N/A |
| 9/30/2016 | 1,706 | 71 | N/A | 102 | N/A |
| 6/30/2016 | 1,693 | 69 | N/A | 104 | N/A |
| 3/31/2016 | 1,615 | 65 | N/A | 95 | N/A |
| 12/31/2015 | 1,537 | 62 | N/A | 86 | N/A |
| 9/30/2015 | 1,465 | 57 | N/A | 79 | N/A |
| 6/30/2015 | 1,392 | 53 | N/A | 71 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: IMCDDas prognostizierte Gewinnwachstum (10.4% pro Jahr) liegt über der Sparquote (2.1%).
Ertrag vs. Markt: IMCDDie Erträge des Unternehmens (10.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Dutch (14% pro Jahr).
Hohe Wachstumserträge: IMCDDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: IMCDDie Einnahmen des Unternehmens (4.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Dutch (9.8% pro Jahr).
Hohe Wachstumseinnahmen: IMCDDie Einnahmen des Unternehmens (4.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: IMCDDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.2%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/25 14:13 |
| Aktienkurs zum Tagesende | 2026/05/25 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
IMCD N.V. wird von 23 Analysten beobachtet. 12 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Gaurav Jain | Barclays |
| James Stewart | Barclays |
| Anil Shenoy | Barclays |